Everomus 0.25 mg Tablet

उत्पाद विवरण

Everomus 0.25 mg Tablet is a targeted anticancer therapy specifically designed to combat various advanced malignancies, including pancreatic, gastric, intestinal, and lung cancers that are inoperable. This medication is particularly effective for postmenopausal women battling hormone receptor-positive, HER2-negative breast cancer, providing a vital treatment option when other therapies are not suitable. Everolimus works by inhibiting a key protein involved in cell growth and proliferation, thus slowing down tumor progression. Additionally, it is indicated for adult patients with advanced renal cell carcinoma who have not responded to treatments like sunitinib or sorafenib. Patients should be aware of potential side effects, including risk of infection and changes in liver function, necessitating regular monitoring during treatment. Everomus represents a crucial advancement in oncology, offering hope to those with challenging cancer diagnoses. Always consult with a healthcare professional before starting treatment to ensure it aligns with your individual health needs.